Small Cell Lung Cancer in Elderly Patients: A Review

Taofeek K. Owonikoko, MD, PhD, and Suresh Ramalingam, MD, Pittsburgh, Pennsylvania, and Atlanta, Georgia

The incidence of small cell lung cancer (SCLC) has decreased in the past 2 decades,1 and approximately 13% of all lung cancer patients have SCLC histology.1,2 Despite this, the proportion and, consequently, population of elderly patients with SCLC continues to rise. No generally accepted definition or chronologic age cutoff exists for elderly; use of the term varies across cultures and time periods. It is, however, a physical manifestation of the biologic process of aging: a progressive decline in cellular, organ, physical, and mental functioning. In the Western world, elderly generally refers to a period of accelerated decline in physical functioning. Some have used the age of 70 years as a cutoff, whereas others differentiate between elderly (< 75 years) and very elderly (≥ 75 years). The oldest old is the term coined for patients older than 85 years.

In the United States, approximately 42% of SCLC cases are diagnosed in patients older than 70 years, and 10% are diagnosed in patients older than 80 years.3 Elderly patients are significantly underrepresented in clinical trials, including those evaluating new treatment modalities for lung cancer.3-6 Although 63% of all cases occur in patients older than 65 years, an analysis of enrollment into 1 U.S. cooperative group trial between 1993 and 1996 showed that a minority of enrollees (25%) were older than 65 years.3 This limits the applicability of data obtained from these clinical trials to the treatment of elderly patients, because physiologic changes related to aging and a higher prevalence of comorbid conditions influence the tolerance of systemic and local therapy and their efficacy.3 This article highlights the management and outcome of SCLC in elderly patients.

Epidemiology

SCLC is a tobacco-related cancer characterized by an explosive growth rate and high sensitivity to chemotherapy. The survival outcomes for patients with SCLC are generally poor. The incidence of SCLC in the United States continues to decline based on registry surveys, and it now constitutes about 13% of all lung cancer cases. However, the disease burden remains great because of a steady increase in the absolute number of cases as the elderly population grows.1,2 Of all lung cancer subtypes, SCLC shows the strongest association with tobacco exposure, with an odds ratio of 18 and 38 for intense tobacco use (> 30 cigarettes per day) and duration of smoking...
Management of Limited-Stage SCLC

Combined Chemotherapy and Radiation

The standard therapy for limited-stage SCLC in the general patient population consists of a combination of platinum-based chemotherapy and external beam thoracic radiation.\(^ {13-15} \) The median age of patients enrolled into the initial trials of combination chemotherapy in SCLC was 65 years or older, reflecting that the regimens were tested in a fair proportion of elderly patients.\(^ {13-14} \) In the pivotal phase III randomized trial that compared cisplatin/etoposide with cyclophosphamide, epirubicin, and vincristine (CEV) for limited-stage disease, the median age of patients was 65 years.\(^ {14} \) The cisplatin/etoposide regimen showed a superior 2-year survival rate (25% vs. 10%). This study supports the observation that elderly patients tolerate the cisplatin/etoposide regimen well and experience benefit.

The development and introduction of carboplatin into clinical use provided an alternative platinum agent with marked reduction in nephrotoxicity and neurotoxicity and a lower incidence of nausea and vomiting.\(^ {16,17} \) Carboplatin was tested as an alternative agent to cisplatin in multiple trials enrolling elderly patients.\(^ {18-22} \) Skarlos et al.\(^ {18} \) compared the efficacy of carboplatin/etoposide combination with cisplatin/etoposide in an unselected, previously untreated population of patients with SCLC (both limited- and extensive-stage). The patient age ranged from 34 to 78 years.\(^ {18} \) This study showed a significant reduction in the incidence of hematologic and nonhematologic toxicities with comparable response rates (57% vs. 58%) and median survival outcomes (12.5 vs. 11.8 months) for the carboplatin-based regimen.\(^ {18} \)

Because area-under-the-curve (AUC)-based dosing was adopted over body surface area–based dosing, several studies have evaluated carboplatin-based regimens in elderly patient populations using the AUC dosing method.\(^ {19,20} \) Okamoto et al.\(^ {19} \) conducted a phase II trial using carboplatin (AUC = 5) with etoposide in an elderly patient population (median age, 73 years). They reported grade 4 leukopenia and thrombocytopenia of 3% and 11%, respectively, with an objective response rate of 75%.\(^ {19} \) A phase I study was recently conducted to evaluate a lower dose of carboplatin in patients older than 75 years. Carboplatin was dosed to achieve an AUC of 4 in combination with etoposide. The response rate of 69% suggested that the efficacy was not compromised by the use of a lower dose of carboplatin.\(^ {23} \) However, grade 4 hematologic toxicity was still noted in 62% of the patients, although the rate of renal toxicity was low at 4%.\(^ {23} \) (Table 1).

Several other studies have evaluated lower doses, reduced number of cycles, or alternative treatment schedules to improve the safety profile of combination regimens in elderly patients. Studies conducted with reduced cycles of chemotherapy and abbreviated radiation therapy have shown acceptable response rates with survival that is comparable with standard courses of therapy.\(^ {21,22} \) Murray et al.\(^ {21} \) investigated the use of only 2 cycles of chemotherapy (cyclophosphamide, doxorubicin, vincristine [CAV] followed by cisplatin and etoposide) with abbreviated concurrent thoracic irradiation to 30 Gy in 55 patients with limited-stage SCLC who were elderly or had poor per-
formance status (median age, 73 years). The objective response rate was 88%, with a complete response rate of 51%, and 18% of the patients were alive at 5 years. Although patients tolerated the regimen well overall, 3 treatment-related deaths occurred.

However, subsequent larger clinical trials that compared full- and reduced-intensity chemotherapy did not substantiate the promising efficacy of this approach (Table 2). Based on these observations, using empiric dose reduction to treat elderly SCLC patients does not necessarily lead to an improved therapeutic index.

The addition of thoracic radiation to platinum-based chemotherapy is associated with survival advantage in limited-stage SCLLC, and confers a 30% increase in disease control in the chest and up to 14% improvement in mortality. However, subset analysis showed that this benefit was mainly confined to patients younger than 55 years, with a trend toward adverse outcome in patients aged 70 years and older. The absolute benefit from thoracic radiation is approximately a 5.4% increase in the 3-year survival rate.

Further efforts at improving the impact of thoracic radiation in limited-stage SCLC led Turrisi et al. to evaluate a hyperfractionated dose in an Intergroup study (INT 0096), administering 45 Gy over 3 weeks in 1.5-Gy dosages twice daily. This large randomized study established the superiority of the hyperfractionated schedule over once-daily fractionation (5-year survival rate, 26% vs. 15%) with a sizable representation of the elderly (31% of patients randomized to the twice-daily radiation therapy were ≥65 years).

This treatment regimen has, however, been difficult to integrate into regular clinical practice, and an analysis of the pattern of care for patients with lung cancer in major United States institutions showed that only 6% of those with SCLC received twice-daily radiation therapy.

Table 1: Clinical Trials of Carboplatin in Elderly Patients With Small Cell Lung Cancer

<table>
<thead>
<tr>
<th>Trial</th>
<th>Median Age (y)</th>
<th>Extent of Disease</th>
<th>Number of Patients</th>
<th>Therapy</th>
<th>Response Rate (%)</th>
<th>Median Survival</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goss et al.</td>
<td>63</td>
<td>LD</td>
<td>29</td>
<td>CT</td>
<td>76 (48% CR)</td>
<td>59 wk</td>
<td>TRT and PCI used in patients with LD</td>
</tr>
<tr>
<td>Michel et al.</td>
<td>72</td>
<td>LD</td>
<td>33</td>
<td>CT</td>
<td>76 (21% CR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evans et al.</td>
<td>67</td>
<td>LD</td>
<td>8</td>
<td>CT</td>
<td>67 (20% CR)</td>
<td>33 wk</td>
<td></td>
</tr>
<tr>
<td>Matsui et al.</td>
<td>N/A</td>
<td>LD</td>
<td>11</td>
<td>CE</td>
<td>88 (50% CR)</td>
<td>12.2 mo</td>
<td></td>
</tr>
<tr>
<td>Okamoto et al.</td>
<td>73</td>
<td>LD</td>
<td>16</td>
<td>CE</td>
<td>93</td>
<td>15.1 mo</td>
<td></td>
</tr>
<tr>
<td>Quoix et al.</td>
<td>&gt; 70</td>
<td>LD/ED</td>
<td>38</td>
<td>CE</td>
<td>76</td>
<td>7.9 mo</td>
<td></td>
</tr>
<tr>
<td>Matsui et al.</td>
<td>&gt; 70</td>
<td>LD</td>
<td>11</td>
<td>CE</td>
<td>94</td>
<td>12 mo</td>
<td></td>
</tr>
<tr>
<td>Larive et al.</td>
<td>74</td>
<td>LD</td>
<td>6</td>
<td>CE</td>
<td>59 (9% CR)</td>
<td>9 mo</td>
<td></td>
</tr>
<tr>
<td>Okamoto et al.</td>
<td>&gt; 70</td>
<td>LD</td>
<td>8</td>
<td>CI</td>
<td>89 (11% CR)</td>
<td>13.3 mo</td>
<td>50% of patients underwent prior treatment</td>
</tr>
</tbody>
</table>

Abbreviations: CE, carboplatin and etoposide; CI, carboplatin and irinotecan; CR, complete response; CT, carboplatin and teniposide; ED, extensive-stage disease; LD, limited-stage disease; N/A, not available; PCI, prophylactic cranial irradiation; TRT, thoracic radiation therapy.
Whether the benefit from hyperfractionated schedules of thoracic radiation applies to the elderly remains controversial based on weak evidence to the contrary from meta-analysis of randomized trials. In the absence of a prospective elderly-specific trial to answer this question, a retrospective analysis was conducted to compare the outcomes between younger and elderly patients enrolled in INT 0096, which evaluated the benefit of once-daily versus split-dose radiotherapy in combination with cisplatin-based chemotherapy. Of the original 417 patients, 381 were eligible for the secondary analysis, of which 50 (13%) were older than 70 years. Comparable outcomes were seen in terms of response rate (80% in...
the elderly vs. 88% for younger patients; \( P = .11 \), 5-year event-free survival (16% for the elderly vs. 19% for younger patients; \( P = .18 \)), duration of response, and time to local failure between elderly and younger patients. Despite the reduced rate of dose delivery in the elderly (78% received the target of 4 cycles of chemotherapy compared with 90% of younger patients), they experienced a significant increase in severe hematologic toxicities (84% vs. 61%; \( P < .01 \)) and fatal toxicities (10% vs. 1%; \( P = .01 \)), which probably contributed to the inferior 5-year overall survival (16% vs. 22%; \( P = .05 \)) recorded for the elderly group in this secondary analysis.\(^{41,47,48}\)

Similar findings were reported in a secondary analysis of a different prospective trial by the North Central Cancer Treatment Group (NCCTG), also designed originally to answer the question of single versus twice-daily radiation in combination with chemotherapy in patients with limited-stage SCLC.\(^{46}\) Of 263 enrolled patients, 54 (21%) were aged 70 years or older. A comparison of this elderly cohort with their younger counterparts showed no significant difference in survival outcome or disease control rate (2-year survival rates of 48% vs. 33%, respectively, and 5-year survival rates of 22% vs. 17%, respectively, for younger vs. elderly patients; \( P = .14 \)). However, a significantly higher incidence of pneumonia in the elderly (0% vs. 6%; \( P = .008 \)) and a tenfold greater treatment-related mortality (0.5% vs. 5.6%; \( P = .03 \)) were seen. Other early-phase clinical trials for limited-stage SCLC have explored alternative strategies with once-daily therapy to a higher total dose of 70 Gy or twice-daily therapy to a higher dose with planned treatment breaks, although these have not been tested specifically in elderly patients.\(^{41,47,48}\)

Based on these data, fit elderly patients with limited-stage SCLC should be offered cisplatin-containing regimens. However, the higher degree of cisplatin-related toxicity warrants particular caution for elderly patients, especially those older than 75 years. These patients tend to have a higher burden of comorbid illnesses and suboptimal performance status, which case a carboplatin-based regimen may represent a reasonable alternative. Thoracic radiation concurrent with chemotherapy remains standard care for treating limited-stage SCLC and should be judiciously used. In elderly patients, twice-daily radiation should only be used for those with excellent performance status and no major comorbid illness, because it is associated with increased treatment-related fatalities in this population.

### Management of Extensive-Stage SCLC

The NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (in this issue; to view the most recent version, please visit the NCCN Web site at www.nccn.org) recommend 4 to 6 cycles of platinum-based combination chemotherapy as standard treatment for patients with extensive-stage SCLC.\(^{49}\) Cisplatin (75–80 mg) or carboplatin (AUC 5–6) in combination with etoposide is the commonly used frontline regimen. Despite the suggestion of a slight survival advantage with cisplatin-containing regimens by 2 meta-analyses of SCLC trials,\(^{10,51}\) the favorable toxicity profile of carboplatin/etoposide over cisplatin/etoposide supports its preferential use in elderly patients, where it has been extensively studied.\(^{23,28,29}\)

In a study of 38 previously untreated elderly patients (age range, 70–88 years) with predominantly extensive-stage disease, the combination of carboplatin (AUC 5) and etoposide (100 mg/m\(^2\) intravenously days 1–3) yielded an objective response rate of 60% and a 1-year survival rate of 26%.\(^{28}\) The main toxicities were hematologic (grade 4 neutropenia of 31% and grade 4 thrombocytopenia of 12%), with no treatment-related renal toxicity. Although 29% of enrolled patients died during therapy, only 2 of the 11 deaths were clearly treatment-related. Moreover, other trials using the same combination of agents at similar doses in elderly patients have shown a favorable safety profile.\(^{29,52,53}\)

The first phase III trial of cisplatin/etoposide versus carboplatin/etoposide in patients who were elderly or had poor performance status with extensive-stage SCLC was published recently.\(^{20}\) The trial enrolled 220 patients with median age of 74 years, with 92% older than 70 years. The response rate was 73% in both arms, with a trend toward better median overall survival for the carboplatin arm (10.6 vs. 9.9 months; \( P = .054 \)). A very high rate of grade 3 or 4 neutropenia was recorded in both arms (95% and 90%), but the rate of grade 3 or 4 infection was relatively low (7% and 6%; \( P = .78 \)), reflecting the use of growth factor support in more than 50% of patients in each cohort. The only significant difference in the toxicity profiles of both regimens is the higher rate of thrombocytopenia in the carboplatin arm (56% vs. 16%; \( P < .01 \)). Although mild renal impairment (grade 1 or 2) was 3 times as common...
with cisplatin as with carboplatin, the clinically relevant grade 3 or 4 renal impairment was rare in both arms. Although the study had limitations, such as the use of potentially suboptimal cisplatin dosage schedule, it nonetheless provided valuable information about the efficacy of the carboplatin/etoposide combination as an alternative to split-dose cisplatin/etoposide in patients who were elderly or had poor performance status.\(^5\)

The other promising regimen tested in extensive-stage SCLC is the cisplatin and irinotecan combination. A phase III study conducted in Japan by Noda et al.\(^5\) showed superior survival with cisplatin/irinotecan over cisplatin/etoposide. This trial randomized 154 patients to receive cisplatin 80 mg/m\(^2\) plus etoposide 100 mg/m\(^2\) (days 1-3) repeated every 4 weeks or cisplatin (60 mg/m\(^2\)) and irinotecan (60 mg/m\(^2\) on days 1, 8, and 15) repeated every 4 weeks. The study was closed early after an interim analysis showed that patients in the irinotecan arm had superior survival (12.8 vs. 9.4 months, P = .002). A significantly higher frequency of grade 3 or 4 diarrhea occurred (16% vs. 0%), which led to the day-15 irinotecan dose to be skipped in 50% of patients. However, this study excluded patients older than 70 years.

In a confirmatory study conducted by Hanna et al.,\(^5\) 331 patients with extensive-stage SCLC were randomized (2:1) to treatment with cisplatin/irinotecan or cisplatin/etoposide. Approximately 45% of patients were older than 65 years. In an attempt to improve the safety profile of the cisplatin-irinotecan regimen, the dose schedule for irinotecan \(60 \text{ mg/m}^2\) was modified to be given only on days 1 and 8. The survival advantage reported in the Japanese trial (Noda et al.\(^5\)) was not observed in this study (9.3 vs. 10.2 months; P = .74) and no significant improvement was recorded in the nonhematologic toxicity profile of the irinotecan regimen (grade 3 or 4 diarrhea, 21.3% vs. 0%; P < .01) despite skipping the day-15 dose. The reason for the negative result in this study remains speculative, including changes in the dose schedule and pharmacogenomic differences between the patient populations. An ongoing trial by SWOG using the exact regimen used in the Japanese trial has completed accrual and will hopefully provide insight into the potential benefit of the irinotecan-based regimen.\(^5\)

Another recently reported study compared the use of irinotecan/carboplatin with etoposide/carboplatin. The study included 209 patients, with approximately 30% of patients older than 70 years. The 2 treatment arms were irinotecan \(175 \text{ mg/m}^2\) intravenously on day 1 with carboplatin (AUC 4) or etoposide \(120 \text{ mg/m}^2\) orally plus carboplatin (AUC 4) every 3 weeks. Both arms had a high-dose delivery rate of 93%, with increased rate of grade 3 or 4 thrombocytopenia in the etoposide arm (26% vs. 11%; P = .05) and increased grade 3 or 4 diarrhea in the irinotecan arm (1% vs. 11%; P = .03). The irinotecan/carboplatin combination was associated with a higher complete response rate (18 vs. 7 patients) and improved median and 1-year survival (8.5 vs. 7.1 months and 34% vs. 24%, respectively; P = .002).\(^5\) In summary, the role of irinotecan for the treatment of SCLC remains to be proven for the North American patient population. Considering the toxicities, particularly diarrhea associated with the combination of irinotecan and a platinum compound, data from elderly-specific trials are warranted before it becomes routine practice.

In conclusion, available evidence supports the treatment of elderly patients with platinum-based chemotherapy for the treatment of extensive-stage SCLC. Given the better toxicity profile and comparable efficacy from the limited data from elderly-specific trials, using carboplatin (in combination with etoposide) is a reasonable alternative to cisplatin-based therapy. The efficacy of irinotecan in SCLC for the general Western population remains to be shown and therefore cannot be recommended for routine use in the elderly patients.

**Prophylactic Cranial Irradiation**

Patients with limited-stage disease who experience complete remission of their disease after combined modality therapy with chemotherapy and thoracic radiation are recommended to undergo prophylactic cranial irradiation (PCI).\(^5\) Several small prospective studies showed reduced incidence of brain metastasis after PCI, but lacked enough power to show a survival advantage.\(^5\) However, results of meta-analyses using pooled individual patient data showed that PCI confers a survival advantage, especially with patients experiencing complete remission.\(^5\) A 54% relative risk reduction occurred in incidence of brain metastasis, which translated into a 5.4- and 8.8-month absolute improvement in 3-year overall survival and disease-free survival respectively.\(^6\) This benefit was shown in all age groups, including patients older than 65 years.\(^6\)

Because of concerns about the potential for neurocognitive impairment, such as memory loss,
Therefore, PCI should be offered to elderly patients with SCLC. In a retrospective analysis of registry data in Vancouver, Canada, Ludbrook et al. showed that PCI was offered at a significantly lower rate to elderly patients older than 75 years. The low rate of PCI in the elderly is probably unrelated to performance status or comorbid conditions, because the same analysis showed that the rate for thoracic radiation, both total-dose and fractionation, were not significantly different among younger and older patient groups. Although substantive evidence from prospective short- and medium-term follow-up of patients is lacking about this potential complication, some studies reported significant neurotoxicity on long-term follow-up of patients with SCLC (Table 3). This problem has been difficult to study because no standard approach to evaluation exists across clinical trials, and the available tools are not well validated. Moreover, the lung cancer patient population is elderly with a higher likelihood of preexisting or newly diagnosed neurocognitive impairment, irrespective of treatment intervention, thereby further confounding the potential relationship between any observed cognitive abnormality and the disease state or treatment modality.

In a prospective study evaluating neuropsychiatric function before PCI in 46 patients with newly diagnosed limited-stage SCLC, 80% had impaired memory, 38% had frontal lobe executive function impairment, and a third had motor deficits. A larger longitudinal study involving 432 patients with SCLC showed that a neurologic diagnosis was established in approximately 65% on long-term follow-up, but approximately half of the abnormalities were present at diagnosis before any intervention. Most patients with SCLC rarely survive long enough to manifest this potential complication of PCI; whereas brain-only relapse is highly fatal because it is poorly responsive to chemotherapy or radiation. Therefore, PCI should be considered and judiciously used in selected elderly patients with limited-stage disease who achieve complete remission, and do not suffer from preexisting neurocognitive impairment or any other comorbidities that may otherwise impair long-term survival.

At diagnosis, approximately 18% to 24% of patients with SCLC have brain metastasis, and up to 70% of patients with extensive-stage disease will develop brain metastasis within 2 years of diagnosis, compared with 47% of patients with limited-stage disease. Despite this, patients with extensive-stage disease were not considered for PCI because of the generally poor outcome, with a 5-year overall survival rate of less than 5% in patients older than 70 years. They were also likely to be excluded from trials evaluating the role of PCI because of findings from earlier meta-analyses showing that the benefit of PCI is limited to patients with good-prognosis disease.

However, evidence is emerging of the usefulness of PCI in patients with extensive-stage SCLC who experienced demonstrable but not necessarily complete response to chemotherapy. Slotman et al. randomized 286 patients with extensive-stage SCLC to undergo PCI or observation after experiencing demonstrable response to 4 to 5 cycles of standard chemotherapy, and noted a reduced incidence of brain metastasis in the PCI arm (16.8% vs. 41.3%; P < .001) and a doubling of the 1-year survival rate (27.1% vs. 13.3%; P < .003). The study excluded patients older than 75 years, and the median participant age was 62 years.

An important limitation of the promising result obtained in this study is the poor standardization of imaging modality and schedule that was adopted across participating centers. The requirement of symptomatic brain metastasis to trigger radiologic evaluation rather than active radiologic surveillance means that some patients with asymptomatic disease inadvertently underwent active treatment in the PCI arm, and their number may be large enough to be responsible for the observed differences. It is well-established that systemic response does not predict brain response and patients with untreated asymptomatic brain metastasis have worse survival than patients with symptomatic disease treated with whole brain radiation.

Despite these limitations, the results of this study support the use of PCI for patients with extensive-stage SCLC after they experience objective response to chemotherapy. However, the applicability of these findings to elderly patients is unclear. Although the study allowed the inclusion of patients up to 75 years of age, most were younger, with median age of 62 years. Therefore, the risk–benefit ratio of PCI for extensive-stage disease in the elderly has not been established. Nonetheless, the impressive positive results of the EORTC study along with the established benefit of PCI in limited-stage disease strengthen the need for a careful evaluation of PCI in the elderly patient population.
Table 3  Incidence of Neurotoxicity on Long-Term Follow-Up of Patients With Small Cell Lung Cancer Treated With Prophylactic Cranial Irradiation

<table>
<thead>
<tr>
<th>Study</th>
<th>Median Follow-Up (y)</th>
<th>Radiation Dose and Fraction</th>
<th>No. of Patients</th>
<th>Isolated Brain Relapse</th>
<th>Rate of Neurotoxicity in Long-Term Survivors</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson et al.</td>
<td>6.7</td>
<td>20–50 Gy</td>
<td>PCI: 17</td>
<td>N/A</td>
<td>62%*</td>
<td>Neurotoxicity measured by score on MMSE</td>
</tr>
<tr>
<td>Lee et al.</td>
<td>≥3</td>
<td>Variable</td>
<td>PCI: 24</td>
<td>N/A</td>
<td>3%</td>
<td></td>
</tr>
<tr>
<td>Ohonoshi et al.</td>
<td>8.5</td>
<td>N/A</td>
<td>PCI: 23</td>
<td>N/A</td>
<td>14%</td>
<td></td>
</tr>
<tr>
<td>Shaw et al.</td>
<td>4</td>
<td>30–38 Gy</td>
<td>LD: 457 PCI</td>
<td>N/A</td>
<td>10% at 5 y</td>
<td>The neurotoxicity rate is for all patients (LD + ED) receiving PCI</td>
</tr>
<tr>
<td>Cull et al.</td>
<td>2</td>
<td>Variable</td>
<td>52</td>
<td>N/A</td>
<td>54%</td>
<td>Patients surviving beyond &gt; 2 y were recalled for neuropsychometric testing</td>
</tr>
<tr>
<td>Arriagada et al.</td>
<td>5</td>
<td>24–36 Gy</td>
<td>PCI: 149</td>
<td>19%</td>
<td>27% at 2 y</td>
<td>The recorded rate of neurotoxicity is the mean frequency at 7 different domains tested</td>
</tr>
<tr>
<td>Gregor et al.</td>
<td>2</td>
<td>24–36 Gy</td>
<td>PCI: 194</td>
<td>30%</td>
<td>29% at 1 y</td>
<td>Recorded rate is mean frequency from 4 different domains tested</td>
</tr>
<tr>
<td>Wolfson et al.</td>
<td>2</td>
<td>30–36 Gy</td>
<td>PCI: 15</td>
<td>13%</td>
<td>6%</td>
<td>Study used twice daily brain irradiation; the only patient with neurologic symptom was found to have brain metastasis</td>
</tr>
</tbody>
</table>

*Scores on MMSE where lower value reflects poorer performance and indicates increased neurotoxicity. Abbreviations: ED, extensive-stage disease; LD, limited-stage disease; MMSE, Mini Mental State Examination; N/A, not available; PCI, prophylactic cranial irradiation.

Salvage Therapy for Resistant and Relapsed Disease

The outcome for patients with relapsed or refractory SCLC remains poor, despite extensive evaluation of several novel agents. A wide array of chemotherapeutic agents, such as ifosfamide, taxanes, gemcitabine, irinotecan, vinorelbine, and topotecan, have all been found to be associated with meager response rates and survival in this setting.69

Intravenous topotecan is the most frequently used regimen in the second-line setting and has received FDA approval for this indication. It was evaluated in a phase III trial against the CAV regimen (cyclophosphamide, doxorubicin, and vincristine) in 211 patients who experienced relapse.62 No significant difference was seen in the response rate (24.3% vs. 18.3%) or median survival (25 vs. 24.7 weeks), but topotecan therapy led to better palliation of symptoms and less interference with daily activities.82 The added value of topotecan in symptom palliation has been confirmed by 2 other randomized studies.83,84 Eckardt et al.83 evaluated oral and intravenous topotecan as a second-line agent in 304 patients ranging in age from 35 to 82 years and reported objective symptom palliation with both formulations. Similarly, O’Brien et al.84 compared oral topotecan with best supportive care in a randomized study of 141 patients with poor performance status who were deemed unsuitable for combination chemotherapy. Topotecan administration was fairly well tolerated, with 99% of the patients taking more than 90% of their prescribed doses. Active therapy was associated with improved survival (13.9 vs. 25.9 weeks; P < .01) and better quality of life, especially in patients whose disease relapsed shortly (within 60 days) after completion of frontline chemotherapy.
Small Cell Lung Cancer in the Elderly

In summary, no elderly-specific studies have been conducted in the salvage therapy setting for SCLC, and therefore definitive recommendations for elderly patients are difficult to make. Importantly, salvage therapy has limited impact on survival and is offered to patients mainly for qualitative benefits. Therefore, it should only be offered to fit elderly patients. The favorable tolerability profile of oral topotecan suggests that it would be a reasonable option for elderly patients when it becomes available for routine use. Elderly patients should be encouraged to participate in clinical trials that use novel agents as monotherapy or in combination with currently available regimens.

Novel Agents on the Horizon

SCLC outcomes are likely to be further improved by the incorporation of novel targeted agents into existing treatment paradigms. Biologic agents can provide additional advantages for the elderly, based on their potential for a favorable tolerability profile. Various classes of compounds, including antiangiogenic agents, antisense Bcl-2 inhibitors, histone deacetylase inhibitors, and sonic hedgehog signaling pathway inhibitors, are in preclinical and clinical development.

The addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to standard chemotherapy (paclitaxel/carboplatin) in patients with recurrent or advanced nonsmall cell lung cancer (NSCLC) led to a 21% and 34% reduction in the risk for death and disease progression, respectively. The enthusiasm generated by this result fueled the ongoing effort to incorporate anti-VEGF therapy into the frontline treatment of SCLC.

ECOG conducted a phase II trial of bevacizumab in combination with frontline chemotherapy (cisplatin and etoposide) in 69 patients (median age, 65.5 years) with extensive-stage SCLC. The response rate was 69% and median progression-free survival was 4.7 months, whereas the median survival was 11.1 months.

A similarly designed study by the CALGB added bevacizumab to combination cisplatin/irinotecan for frontline therapy of extensive-stage SCLC. In a preliminary analysis of the 70 enrolled patients, median progression-free survival was measured at 7.1 months, with median overall survival of 11.7 months. Although the study failed in its primary end point of exceeding the median survival of 12.8 months reported with cisplatin/irinotecan combination in Japanese patients, it modestly surpassed the median overall survival reported from most of the recent trials of extensive-stage SCLC in patients in the United States. Although these results are promising, none were derived from an elderly-specific or elderly-enriched patient population.

In the ECOG 4599 trial studying bevacizumab in advanced or relapsed NSCLC, more than 40% of enrolled patients were older than 65 years, indicating a fair representation and suggesting that this would be generalizable to the entire population of elderly patients with NSCLC. However, an unplanned secondary analysis of the data compared outcome according to the type of treatment received within the elderly (> 70 years) and younger (< 70 years) patient groups. The addition of bevacizumab to standard chemotherapy led to an increased response rate in both the elderly (29% vs. 17%) and younger patients (36% vs. 14%). However, although this translated into an improved median survival time within the younger group (12.8 vs. 9.6 months; \( P = .0027 \)), no improvement occurred in the elderly group (12.1 vs. 11.3 months; \( P = .4 \)).

Although secondary analysis to answer questions not raised a priori is unreliable and may be misleading, the increased toxicity and consequent increase in treatment-related deaths (1.8% vs. 6.3%) observed in elderly patients treated with bevacizumab compared with those treated with chemotherapy alone calls for caution in integrating targeted agents in elderly patients. Nevertheless, the increasing number of novel targeted agents entering the clinical arena is promising for transforming the treatment of SCLC, especially in the elderly. It will be important to study these agents and combinations in elderly-specific or -enriched trials to obtain relevant safety and efficacy data that can be applied to treatment.

Conclusions

The burden of SCLC in the elderly population remains large despite a decline in incidence in recent decades. Limited progress has been achieved in the past decade to improve the outcome for patients with SCLC. Platinum-based combination therapy should be used in the frontline setting for fit elderly patients, with addition of thoracic radiotherapy, preferably as a single daily dose. PCI benefits elderly patients with limited-stage SCLC and should be judiciously used. Although
the potential risk for neurotoxicity is a concern, this beneficial intervention should not be withheld without conclusive negative evidence. However, in extensive-stage SCLC, the therapeutic index of PCI in elderly patients is yet to be evaluated. The ideal salvage therapy for relapsed disease in the elderly has not been well studied and requires the decision regarding therapy and the choice of agents to be individualized, with particular attention to quality of life. In this regard, topotecan in parenteral and oral formulations is tolerable and has reproducible activity in refractory disease. It has promise for treating the elderly because it improves symptom palliation. Although the era of biologic agents is in full bloom in oncology care, SCLC therapy has yet to benefit from the promise held by these agents.

References

32. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped


Owonikoko and Ramalingam


